Pieris Pharmaceuticals Inc (PIRS) Expected to Earn Q1 2018 Earnings of ($0.22) Per Share
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) – Investment analysts at Oppenheimer Holdings issued their Q1 2018 earnings estimates for shares of Pieris Pharmaceuticals in a research report issued on Thursday. Oppenheimer Holdings analyst H. Singh anticipates that the biotechnology company will post earnings per share of ($0.22) for the quarter. Oppenheimer Holdings has a “Buy” rating and a $9.00 price target on the stock. Oppenheimer Holdings also issued estimates for Pieris Pharmaceuticals’ Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.20) EPS, FY2019 earnings at ($0.88) EPS and FY2020 earnings at ($0.85) EPS.
Separately, TheStreet raised shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Wednesday, May 3rd.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 3.80 on Monday. The firm’s market cap is $163.62 million. The stock has a 50 day moving average price of $2.74 and a 200-day moving average price of $2.08. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $4.17.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by $0.35. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 364.96% and a negative return on equity of 60.26%.
Several hedge funds have recently added to or reduced their stakes in PIRS. Renaissance Technologies LLC purchased a new stake in Pieris Pharmaceuticals during the first quarter valued at approximately $661,000. Morgan Stanley raised its stake in Pieris Pharmaceuticals by 5.3% in the first quarter. Morgan Stanley now owns 191,917 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 9,733 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Pieris Pharmaceuticals by 23.5% in the first quarter. Sphera Funds Management LTD. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the last quarter. Creative Planning raised its stake in Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 13,700 shares during the last quarter. Finally, BVF Inc. IL raised its stake in Pieris Pharmaceuticals by 321.2% in the third quarter. BVF Inc. IL now owns 1,016,593 shares of the biotechnology company’s stock valued at $1,858,000 after buying an additional 775,241 shares during the last quarter. 47.58% of the stock is owned by institutional investors and hedge funds.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.